Ellington Management Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Ellington Management Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-800	Closed	-$300K	–	720
2019 Q4	$300K	Sell	800 -2,100	-72%	-$707K	0.06%	308
2019 Q3	$804K	Buy	2,900 +1,700	+142%	+$503K	0.15%	149
2019 Q2	$376K	Buy	+1,200	New	+$400K	0.06%	301
2018 Q4	–	Sell	-2,000	Closed	-$808K	–	574
2018 Q3	$808K	Sell	2,000 -300	-13%	-$114K	0.22%	126
2018 Q2	$793K	Buy	+2,300	New	+$719K	0.06%	102
2016 Q1	–	Sell	-500	Closed	-$271K	–	663
2015 Q4	$271K	Buy	+500	New	+$271K	0.1%	318
2014 Q1	–	Sell	-800	Closed	-$220K	–	737
2013 Q4	$220K	Sell	800 -1,900	-70%	-$546K	0.08%	417
2013 Q3	$845K	Buy	2,700 +100	+4%	+$26.3K	0.16%	153
2013 Q2	$585K	Buy	+2,600	New	+$605K	0.11%	245

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Ellington Management Group's REGN Position: Q1 2020 in Review

Ellington Management Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 800 shares — an estimated $300K sold.

Ellington Management Group first reported a position in REGN in Q2 2013 and held it in 9 quarters. The position peaked at $845K in Q3 2013. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

Ellington Management Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Ellington Management Group sold 800 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $300K.
Ellington Management Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Ellington Management Group's Regeneron Pharmaceuticals position peaked at $845K in Q3 2013.
816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Ellington Management Group's 13F filing for Q1 2020, filed 15 May 2020.